Literature DB >> 18971855

[Effectiveness of topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft].

A Aydin1, K Karadayi, U Aykan, G Can, K Colakoglu, A H Bilge.   

Abstract

AIM: To study the efficacy and safety of topical ciclosporin A (CsA) as an adjunctive therapy after surgical treatment of primary pterygium including excision and limbal conjunctival autograft (LCA) with respect to postoperative pain and complications. PATIENTS AND
METHOD: A prospective randomized clinical study was conducted in 60 consecutive patients with primary pterygium. Sixty eyes were operated on using the same surgical technique including excision and LCA. Thirty eyes were randomly treated with topical 0.05% CsA for 3 months after the surgery as a supplement to the standard topical therapy. All patients were followed for postoperative pain using the visual analog scale (VAS) for 1 week after surgery and for complications including recurrences for a period of 1 year.
RESULTS: The average VAS was significantly lower in the CsA group (p=0.034). There was only one recurrence (3.4%) in the CsA group (n=28) and five recurrences (17.9%) in the control group (n=29). The other complications were substantial graft scarring (one in the CsA group, three in the control group), Tenon's granuloma (0/2), and fibrovascular proliferation (1/3). The ratio of the cases with no complications was statistically significantly higher in the CsA group (p=0.017).
CONCLUSION: This study shows that topical CsA therapy after pterygium surgery may reduce postoperative pain and also decreases complications including recurrences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971855     DOI: 10.1016/s0181-5512(08)74384-5

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  7 in total

1.  In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts.

Authors:  Magda Massae Hata Viveiros; Fabiano Yutaka Kakizaki; Laura Almeida Hércules; Carlos Roberto Padovani; João Manuel Grisi Candeias; Silvana Artioli Schellini
Journal:  Int Ophthalmol       Date:  2015-08-11       Impact factor: 2.031

2.  The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery.

Authors:  Ece Turan-Vural; Banu Torun-Acar; S Argun Kivanc; Suphi Acar
Journal:  Clin Ophthalmol       Date:  2011-06-29

3.  Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.

Authors:  Yeoun-Hee Kim; Jae-Chang Jung; Sang Il Gum; Su-Bin Park; Jin Yeul Ma; Yong Il Kim; Kyoo Won Lee; Young Jeung Park
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

Review 4.  How to minimize pterygium recurrence rates: clinical perspectives.

Authors:  Raffaele Nuzzi; Federico Tridico
Journal:  Clin Ophthalmol       Date:  2018-11-19

5.  The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery.

Authors:  Ayse Sevgi Karadag; Emre Guler; Emre Guler
Journal:  Beyoglu Eye J       Date:  2021-09-27

6.  Comparison of Pterygium Recurrence with and without Using Postsurgical Topical Cyclosporin A 0.05%: A Randomized Clinical Trial.

Authors:  Yousef Alizadeh; Mitra Akbari; Reza Soltani Moghadam; Maryam Dourandeesh; Zahra Moravej
Journal:  J Curr Ophthalmol       Date:  2022-07-26

Review 7.  Evaluating the Efficacy and Safety of Different Pterygium Surgeries: A Review of the Literature.

Authors:  Marcin Palewski; Agnieszka Budnik; Joanna Konopińska
Journal:  Int J Environ Res Public Health       Date:  2022-09-09       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.